JP2013521226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013521226A5 JP2013521226A5 JP2012555127A JP2012555127A JP2013521226A5 JP 2013521226 A5 JP2013521226 A5 JP 2013521226A5 JP 2012555127 A JP2012555127 A JP 2012555127A JP 2012555127 A JP2012555127 A JP 2012555127A JP 2013521226 A5 JP2013521226 A5 JP 2013521226A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mixture
- apixaban
- granulation
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 238000000034 method Methods 0.000 claims 13
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims 7
- 229960003886 apixaban Drugs 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 7
- 238000005469 granulation Methods 0.000 claims 5
- 230000003179 granulation Effects 0.000 claims 5
- 238000002356 laser light scattering Methods 0.000 claims 5
- 239000002994 raw material Substances 0.000 claims 5
- 238000007908 dry granulation Methods 0.000 claims 4
- 238000002156 mixing Methods 0.000 claims 4
- 239000000314 lubricant Substances 0.000 claims 3
- 238000005550 wet granulation Methods 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000007888 film coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000004513 sizing Methods 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30805610P | 2010-02-25 | 2010-02-25 | |
| US61/308,056 | 2010-02-25 | ||
| PCT/US2011/025994 WO2011106478A2 (en) | 2010-02-25 | 2011-02-24 | Apixaban formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015226794A Division JP6033945B2 (ja) | 2010-02-25 | 2015-11-19 | アピキサバン製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013521226A JP2013521226A (ja) | 2013-06-10 |
| JP2013521226A5 true JP2013521226A5 (https=) | 2014-04-10 |
| JP5846647B2 JP5846647B2 (ja) | 2016-01-20 |
Family
ID=43901603
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012555127A Active JP5846647B2 (ja) | 2010-02-25 | 2011-02-24 | アピキサバン製剤 |
| JP2015226794A Active JP6033945B2 (ja) | 2010-02-25 | 2015-11-19 | アピキサバン製剤 |
| JP2016209347A Active JP6192078B2 (ja) | 2010-02-25 | 2016-10-26 | アピキサバン製剤 |
| JP2017149644A Active JP6577980B2 (ja) | 2010-02-25 | 2017-08-02 | アピキサバン製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015226794A Active JP6033945B2 (ja) | 2010-02-25 | 2015-11-19 | アピキサバン製剤 |
| JP2016209347A Active JP6192078B2 (ja) | 2010-02-25 | 2016-10-26 | アピキサバン製剤 |
| JP2017149644A Active JP6577980B2 (ja) | 2010-02-25 | 2017-08-02 | アピキサバン製剤 |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US9326945B2 (https=) |
| EP (7) | EP3662899A1 (https=) |
| JP (4) | JP5846647B2 (https=) |
| KR (4) | KR20170126016A (https=) |
| CN (3) | CN109602716A (https=) |
| AU (1) | AU2011220775B2 (https=) |
| BR (1) | BR112012021337A8 (https=) |
| CA (1) | CA2791171C (https=) |
| CO (1) | CO6640207A2 (https=) |
| CY (5) | CY1117434T1 (https=) |
| DK (5) | DK3251660T3 (https=) |
| ES (5) | ES2767848T3 (https=) |
| HK (2) | HK1243945B (https=) |
| HR (5) | HRP20160179T1 (https=) |
| HU (4) | HUE043932T2 (https=) |
| IL (3) | IL309564A (https=) |
| IN (1) | IN2012DN06587A (https=) |
| LT (4) | LT3257500T (https=) |
| MX (3) | MX353145B (https=) |
| NZ (1) | NZ601738A (https=) |
| PE (3) | PE20130378A1 (https=) |
| PL (5) | PL3251660T3 (https=) |
| PT (5) | PT3246021T (https=) |
| RS (5) | RS54559B1 (https=) |
| RU (1) | RU2685724C2 (https=) |
| SG (2) | SG10201501349VA (https=) |
| SI (5) | SI3251660T1 (https=) |
| SM (5) | SMT201900650T1 (https=) |
| TR (1) | TR201903195T4 (https=) |
| WO (1) | WO2011106478A2 (https=) |
| ZA (1) | ZA201205807B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2012DN06587A (https=) | 2010-02-25 | 2015-10-23 | Bristol Myers Squibb Co | |
| US20150018386A1 (en) * | 2012-03-06 | 2015-01-15 | Cadila Healthcare Limited | Amorphous form of apixaban, process of preparation and compositions thereof |
| US20150272891A1 (en) * | 2012-05-24 | 2015-10-01 | Ratiopharm Gmbh | Dosage forms comprising apixaban and matrix former |
| MY179191A (en) | 2012-09-26 | 2020-10-30 | Pfizer | Apixaban liquid formulations |
| CN102908324A (zh) * | 2012-10-31 | 2013-02-06 | 南京正科制药有限公司 | 一种阿哌沙班片 |
| EP2752414A1 (en) | 2013-01-04 | 2014-07-09 | Sandoz AG | Crystalline form of apixaban |
| CZ2013305A3 (cs) | 2013-04-23 | 2014-11-05 | Zentiva, K.S. | Nové krystalické formy APIXABANU a způsob jejich přípravy |
| US20160113912A1 (en) * | 2013-06-18 | 2016-04-28 | Cadila Healthcare Limited | An improved process for the preparation of apixaban and intermediates thereof |
| EP2907507A1 (en) | 2014-02-17 | 2015-08-19 | Sandoz Ag | Pharmaceutical composition comprising apixaban |
| CN103830199A (zh) * | 2014-03-24 | 2014-06-04 | 重庆东得医药科技有限公司 | 含阿哌沙班的药用制剂及其制备方法 |
| US10085993B2 (en) | 2014-07-25 | 2018-10-02 | Novartis Ag | Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide |
| CN104316637B (zh) * | 2014-10-30 | 2016-08-17 | 江苏宝众宝达药业有限公司 | 高效液相色谱法测定阿哌沙班清洗残留量 |
| US9603846B2 (en) | 2014-11-25 | 2017-03-28 | Cadila Healthcare Limited | Process for the preparation of apixaban |
| BR112017016393A2 (pt) * | 2015-05-08 | 2018-03-27 | Wockhardt Limited | composições farmacêuticas estáveis compreendendo agente antibacteriano |
| EP3380083A1 (en) | 2015-11-26 | 2018-10-03 | Zentiva, K.S. | Preparation of a drug form containing amorphous apixaban |
| CN106913528A (zh) * | 2015-12-25 | 2017-07-04 | 中美华世通生物医药科技（武汉）有限公司 | 阿哌沙班微丸及其制备方法 |
| WO2017121340A1 (zh) * | 2016-01-12 | 2017-07-20 | 广东东阳光药业有限公司 | 阿哌沙班固体组合物及其制备方法 |
| EP3195860A1 (de) * | 2016-01-22 | 2017-07-26 | STADA Arzneimittel AG | Verfahren zur herstellung eines apixaban-granulates |
| WO2017163170A1 (en) * | 2016-03-21 | 2017-09-28 | Sun Pharmaceutical Industries Limited | Pharmaceutical composition comprising apixaban |
| WO2017182908A1 (en) * | 2016-04-18 | 2017-10-26 | Emcure Pharmaceuticals Limited | Pharmaceutical compositions of apixaban |
| EP3243505A1 (en) | 2016-05-13 | 2017-11-15 | Zaklady Farmaceutyczne Polpharma SA | A pharmaceutical composition comprising amorphous apixaban |
| CN106822006B (zh) * | 2016-06-08 | 2020-08-28 | 北京普德康利医药科技发展有限公司 | 一种阿哌沙班片及其制备方法 |
| WO2017221209A1 (en) | 2016-06-23 | 2017-12-28 | Lupin Limited | Pharmaceutical formulations of apixaban |
| RU2725153C1 (ru) * | 2016-09-24 | 2020-06-30 | Кбп Биосаенсес Ко., Лтд | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение |
| CN106420651B (zh) * | 2016-09-28 | 2019-03-08 | 乐普药业股份有限公司 | 一种阿哌沙班片的制备方法 |
| US11510909B2 (en) | 2017-02-17 | 2022-11-29 | Unichem Laboratories Ltd. | Pharmaceutical composition of apixaban |
| JP7044115B2 (ja) | 2017-11-27 | 2022-03-30 | 三菱ケミカル株式会社 | ゴム含有グラフト重合体組成物を含む熱可塑性樹脂の樹脂改質用組成物、ゴム含有グラフト重合体含有樹脂組成物およびその成形体 |
| KR20190075566A (ko) | 2017-12-21 | 2019-07-01 | 전자부품연구원 | 다중 센서를 활용한 용변 습관 모니터링 시스템 및 방법 |
| TR201722523A2 (tr) | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Api̇ksaban i̇çeren kati oral farmasöti̇k kompozi̇syonlar |
| CN108236604A (zh) * | 2018-02-07 | 2018-07-03 | 中国药科大学 | 阿哌沙班柔性脂质体 |
| PT3781132T (pt) | 2018-04-16 | 2024-05-16 | Pfizer | Formulações de apixabano |
| KR20190130411A (ko) * | 2018-05-14 | 2019-11-22 | 신일제약주식회사 | 아픽사반 약제학적 제제 및 그의 제조방법 |
| BR112021002675A2 (pt) | 2018-08-14 | 2021-05-11 | Jiangsu Hengrui Medicine Co., Ltd. | composições farmacêuticas, métodos para preparar as referidas composições e uso das mesmas |
| EP3666773A1 (en) | 2018-12-11 | 2020-06-17 | KRKA, D.D., Novo Mesto | Process for preparing apixaban |
| EP3669866A1 (en) | 2018-12-19 | 2020-06-24 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising apixaban |
| CN111377915B (zh) * | 2018-12-30 | 2023-10-24 | 鲁南制药集团股份有限公司 | 一种吡唑并-吡啶酮化合物晶型d |
| CN109464415B (zh) * | 2019-01-09 | 2021-08-17 | 常州恒邦药业有限公司 | 阿哌沙班药物组合物及其制备方法 |
| HUE073416T2 (hu) | 2019-11-13 | 2026-01-28 | Unison Pharmaceuticals Pvt Ltd | Az apixaban orálisan dezintegrálódó gyógyszerkészítményei |
| CN111214442B (zh) * | 2020-02-13 | 2021-12-10 | 山东百诺医药股份有限公司 | 一种阿哌沙班共微粉化物 |
| CN111494326A (zh) * | 2020-04-11 | 2020-08-07 | 南京正大天晴制药有限公司 | 一种阿哌沙班片及其制备方法 |
| WO2022115052A1 (en) | 2020-11-27 | 2022-06-02 | Santa Farma Ilac Sanayii A.S. | Improved wet granulation processes for apixaban comprising formulations |
| WO2022115051A1 (en) | 2020-11-27 | 2022-06-02 | Santa Farma Ilac Sanayii A.S. | Direct compression method for non-micronised apixaban formulations |
| WO2022150030A2 (en) | 2021-01-08 | 2022-07-14 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A film coated tablet of apixaban |
| TR202100250A2 (tr) | 2021-01-08 | 2022-07-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Api̇ksaban i̇çeren fi̇lm kapli tablet |
| JP2022112698A (ja) * | 2021-01-22 | 2022-08-03 | 東和薬品株式会社 | アピキサバン含有医薬組成物 |
| GB202102575D0 (en) | 2021-02-23 | 2021-04-07 | Teva Pharmaceutical Industries Ltd | Fixed-dose pharmaceutical compositions |
| IL309098A (en) * | 2021-06-08 | 2024-02-01 | Taho Pharmaceuticals Ltd | Apixaban layer product and its uses |
| US12214075B2 (en) | 2021-10-27 | 2025-02-04 | Pharma-Data Research And Development Single Member S.A. | Apixaban suspension and preparation method |
| JP7834007B2 (ja) * | 2022-10-12 | 2026-03-23 | 日本ジェネリック株式会社 | アピキサバンを含有する錠剤 |
| KR102760108B1 (ko) | 2024-04-09 | 2025-01-24 | 에바바이오 주식회사 | 수용해도와 투과도를 향상시켜 생체이용률이 개선된 무정형 아픽사반 고체분산체 제제 및 그의 서방성 정제 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150366A (en) | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
| DE69921358T2 (de) | 1998-12-23 | 2006-03-09 | Bristol-Myers Squibb Pharma Co. | Stickstoffhaltige heterobicyclen als faktor-xa-hemmer |
| TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| CA2461202C (en) | 2001-09-21 | 2011-07-12 | Donald Pinto | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| WO2004084943A1 (en) * | 2003-03-19 | 2004-10-07 | Beth Israel Deaconess Medical Center, Inc | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation |
| US20050059719A1 (en) * | 2003-09-16 | 2005-03-17 | Badawy Sherif Ibrahim Farag | Solid dosage formulation containing a Factor Xa inhibitor and method |
| DE10355461A1 (de) * | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| US7434502B2 (en) | 2004-07-21 | 2008-10-14 | Husqvarna Outdoor Products Inc. | Bar knob with cam-operated locking mechanism |
| US20060016084A1 (en) * | 2004-07-24 | 2006-01-26 | Ching-Lin Liao | Laser-Based datum instrument |
| US7396932B2 (en) | 2004-09-28 | 2008-07-08 | Bristol-Myers Squibb Company | Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| US20060160841A1 (en) * | 2005-01-19 | 2006-07-20 | Chenkou Wei | Crystallization via high-shear transformation |
| GB0507577D0 (en) * | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| US20070191306A1 (en) | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
| WO2007053904A1 (en) | 2005-11-10 | 2007-05-18 | Alphapharm Pty Ltd | Process to control particle size |
| US20070259913A1 (en) | 2006-05-04 | 2007-11-08 | David Deitchman | Prophylaxis of thromboembolic events in cancer patients |
| US20090285887A1 (en) * | 2006-09-12 | 2009-11-19 | Omar Abdelfattah Abu-Baker | Pharmaceutical Composition Comprising A Plurality of Mini-Tablets Comprising A Factor XA Inhibitor |
| FI20080351A0 (fi) | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi |
| MX2009011755A (es) * | 2007-05-02 | 2010-02-12 | Portola Pharm Inc | Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas. |
| US20090143343A1 (en) * | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| EP2291233B1 (en) * | 2008-05-09 | 2019-09-04 | Atacama Labs Oy | Method for dry granulation |
| US20110159050A1 (en) * | 2008-07-11 | 2011-06-30 | Basf Se | Amphiphilic proteins as morphology modifiers |
| US20100018486A1 (en) * | 2008-07-22 | 2010-01-28 | Hung-Tao Liu | Cathode energy fuel-saving device |
| NZ624963A (en) * | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| SMT202000093T1 (it) | 2009-06-16 | 2020-03-13 | Pfizer | Forme di dosaggio di apixaban |
| IN2012DN06587A (https=) * | 2010-02-25 | 2015-10-23 | Bristol Myers Squibb Co | |
| AU2011225810B2 (en) * | 2010-03-10 | 2014-11-06 | Lupin Limited | Rifaximin ready-to-use suspension |
-
2011
- 2011-02-24 IN IN6587DEN2012 patent/IN2012DN06587A/en unknown
- 2011-02-24 MX MX2015007763A patent/MX353145B/es unknown
- 2011-02-24 DK DK17175788T patent/DK3251660T3/da active
- 2011-02-24 DK DK17175864.2T patent/DK3246021T3/da active
- 2011-02-24 CN CN201810769647.9A patent/CN109602716A/zh active Pending
- 2011-02-24 PE PE2012001362A patent/PE20130378A1/es not_active Application Discontinuation
- 2011-02-24 CN CN201180011229XA patent/CN102770126A/zh active Pending
- 2011-02-24 WO PCT/US2011/025994 patent/WO2011106478A2/en not_active Ceased
- 2011-02-24 PE PE2015002402A patent/PE20160042A1/es unknown
- 2011-02-24 SI SI201131811T patent/SI3251660T1/sl unknown
- 2011-02-24 EP EP20151141.7A patent/EP3662899A1/en not_active Withdrawn
- 2011-02-24 EP EP17175788.3A patent/EP3251660B1/en not_active Revoked
- 2011-02-24 PT PT171758642T patent/PT3246021T/pt unknown
- 2011-02-24 DK DK17178613T patent/DK3257500T3/da active
- 2011-02-24 PL PL17175788T patent/PL3251660T3/pl unknown
- 2011-02-24 RU RU2012140690A patent/RU2685724C2/ru active
- 2011-02-24 SM SM20190650T patent/SMT201900650T1/it unknown
- 2011-02-24 DK DK15190823.3T patent/DK3017811T3/en active
- 2011-02-24 PL PL17178613T patent/PL3257500T3/pl unknown
- 2011-02-24 HU HUE15190823A patent/HUE043932T2/hu unknown
- 2011-02-24 PL PL15190823T patent/PL3017811T3/pl unknown
- 2011-02-24 EP EP17175864.2A patent/EP3246021B1/en not_active Revoked
- 2011-02-24 KR KR1020177031997A patent/KR20170126016A/ko not_active Ceased
- 2011-02-24 SG SG10201501349VA patent/SG10201501349VA/en unknown
- 2011-02-24 PT PT171786130T patent/PT3257500T/pt unknown
- 2011-02-24 NZ NZ601738A patent/NZ601738A/en unknown
- 2011-02-24 CN CN201811354155.XA patent/CN109602713A/zh active Pending
- 2011-02-24 LT LT17178613T patent/LT3257500T/lt unknown
- 2011-02-24 HU HUE17178613A patent/HUE047140T2/hu unknown
- 2011-02-24 SG SG2012055547A patent/SG182750A1/en unknown
- 2011-02-24 MX MX2017016605A patent/MX364938B/es unknown
- 2011-02-24 HU HUE17175788A patent/HUE047139T2/hu unknown
- 2011-02-24 BR BR112012021337A patent/BR112012021337A8/pt not_active Application Discontinuation
- 2011-02-24 SI SI201131665T patent/SI3017811T1/sl unknown
- 2011-02-24 JP JP2012555127A patent/JP5846647B2/ja active Active
- 2011-02-24 EP EP19199147.0A patent/EP3643301A1/en not_active Withdrawn
- 2011-02-24 RS RS20160088A patent/RS54559B1/sr unknown
- 2011-02-24 LT LT17175788T patent/LT3251660T/lt unknown
- 2011-02-24 PT PT117072843T patent/PT2538925E/pt unknown
- 2011-02-24 PE PE2020000316A patent/PE20210468A1/es unknown
- 2011-02-24 SI SI201131813T patent/SI3257500T1/sl unknown
- 2011-02-24 ES ES17175864T patent/ES2767848T3/es active Active
- 2011-02-24 SM SM20190212T patent/SMT201900212T1/it unknown
- 2011-02-24 US US13/579,796 patent/US9326945B2/en active Active
- 2011-02-24 DK DK11707284.3T patent/DK2538925T3/en active
- 2011-02-24 PT PT15190823T patent/PT3017811T/pt unknown
- 2011-02-24 EP EP11707284.3A patent/EP2538925B1/en not_active Revoked
- 2011-02-24 ES ES17175788T patent/ES2758031T3/es active Active
- 2011-02-24 PL PL17175864T patent/PL3246021T3/pl unknown
- 2011-02-24 KR KR1020127022152A patent/KR101796300B1/ko not_active Ceased
- 2011-02-24 SM SM20190649T patent/SMT201900649T1/it unknown
- 2011-02-24 AU AU2011220775A patent/AU2011220775B2/en active Active
- 2011-02-24 SI SI201130742T patent/SI2538925T1/sl unknown
- 2011-02-24 RS RS20190290A patent/RS58699B1/sr unknown
- 2011-02-24 TR TR2019/03195T patent/TR201903195T4/tr unknown
- 2011-02-24 ES ES15190823T patent/ES2714363T3/es active Active
- 2011-02-24 KR KR1020217031947A patent/KR20210124532A/ko not_active Ceased
- 2011-02-24 SM SM20200034T patent/SMT202000034T1/it unknown
- 2011-02-24 KR KR1020237035193A patent/KR20230149861A/ko not_active Ceased
- 2011-02-24 IL IL309564A patent/IL309564A/en unknown
- 2011-02-24 HU HUE11707284A patent/HUE027168T2/en unknown
- 2011-02-24 EP EP17178613.0A patent/EP3257500B1/en not_active Revoked
- 2011-02-24 LT LTEP15190823.3T patent/LT3017811T/lt unknown
- 2011-02-24 LT LTEP17175864.2T patent/LT3246021T/lt unknown
- 2011-02-24 RS RS20191493A patent/RS59593B1/sr unknown
- 2011-02-24 SI SI201131827T patent/SI3246021T1/sl unknown
- 2011-02-24 HR HRP20160179TT patent/HRP20160179T1/hr unknown
- 2011-02-24 MX MX2012009244A patent/MX2012009244A/es active IP Right Grant
- 2011-02-24 PT PT171757883T patent/PT3251660T/pt unknown
- 2011-02-24 EP EP15190823.3A patent/EP3017811B1/en not_active Revoked
- 2011-02-24 RS RS20191468A patent/RS59576B1/sr unknown
- 2011-02-24 PL PL11707284T patent/PL2538925T3/pl unknown
- 2011-02-24 RS RS20200017A patent/RS59810B1/sr unknown
- 2011-02-24 ES ES11707284.3T patent/ES2562279T3/es active Active
- 2011-02-24 CA CA2791171A patent/CA2791171C/en active Active
- 2011-02-24 ES ES17178613T patent/ES2757603T3/es active Active
-
2012
- 2012-07-22 IL IL221064A patent/IL221064A0/en unknown
- 2012-08-01 ZA ZA2012/05807A patent/ZA201205807B/en unknown
- 2012-09-05 CO CO12152138A patent/CO6640207A2/es not_active Application Discontinuation
-
2015
- 2015-11-19 JP JP2015226794A patent/JP6033945B2/ja active Active
-
2016
- 2016-02-17 SM SM201600049T patent/SMT201600049B/xx unknown
- 2016-03-07 CY CY20161100194T patent/CY1117434T1/el unknown
- 2016-03-31 US US15/086,447 patent/US20160243101A1/en not_active Abandoned
- 2016-10-26 JP JP2016209347A patent/JP6192078B2/ja active Active
-
2017
- 2017-03-30 US US15/474,236 patent/US20170202824A1/en not_active Abandoned
- 2017-03-30 US US15/474,264 patent/US20170202825A1/en not_active Abandoned
- 2017-04-27 IL IL251991A patent/IL251991A0/en unknown
- 2017-08-02 JP JP2017149644A patent/JP6577980B2/ja active Active
-
2018
- 2018-03-14 HK HK18103542.7A patent/HK1243945B/en not_active IP Right Cessation
- 2018-03-14 HK HK18103544.5A patent/HK1243947B/en not_active IP Right Cessation
-
2019
- 2019-02-28 CY CY20191100249T patent/CY1121597T1/el unknown
- 2019-03-05 HR HRP20190430TT patent/HRP20190430T8/hr unknown
- 2019-11-15 HR HRP20192064TT patent/HRP20192064T1/hr unknown
- 2019-11-18 HR HRP20192069TT patent/HRP20192069T1/hr unknown
- 2019-11-21 CY CY20191101226T patent/CY1122382T1/el unknown
- 2019-11-22 CY CY20191101231T patent/CY1122384T1/el unknown
-
2020
- 2020-01-13 HR HRP20200046TT patent/HRP20200046T1/hr unknown
- 2020-01-28 CY CY20201100074T patent/CY1122529T1/el unknown
- 2020-05-14 US US15/931,910 patent/US20200375968A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013521226A5 (https=) | ||
| RU2012140690A (ru) | Композиции апиксабана | |
| ES2688889T3 (es) | Proceso de mezcla sin disolvente para el recubrimiento de ingredientes farmacéuticos | |
| RU2221553C2 (ru) | Способ изготовления округлых гранул | |
| JP2015535289A5 (https=) | ||
| JP2010508929A5 (https=) | ||
| RU2016152167A (ru) | Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения | |
| JP2011525501A5 (https=) | ||
| JP2012509329A5 (https=) | ||
| TW202510884A (zh) | 包含Akt蛋白質激酶抑制劑之醫藥組合物 | |
| JP2009503156A5 (https=) | ||
| CN101166516A (zh) | 稳定的唑尼沙胺药物制剂及其制备方法 | |
| CA3104820A1 (en) | Processing method for drug substance particles of non-uniform particle size | |
| US7186293B2 (en) | Agglomerated starch compositions | |
| CN106822155B (zh) | 依非韦伦、拉米夫定及富马酸替诺福韦酯三联复方片中片及其制备方法 | |
| JP2012087073A (ja) | コーティング粒子の製造方法、及び該製造方法で製造されたコーティング粒子 | |
| Zhai et al. | Gastroretentive extended-release floating granules prepared using a novel fluidized hot melt granulation (FHMG) technique | |
| Chew et al. | A review on the development of granulation technology in the past two decades | |
| CN105434375A (zh) | 一种左乙拉西坦片剂及制备方法 | |
| CN101340896A (zh) | 含有低溶解性药物的压缩的固体剂型和其制备方法 | |
| CN104688706B (zh) | 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法 | |
| RU2697660C2 (ru) | Таблетка и способ ее получения | |
| JP2017081859A (ja) | テルミサルタン含有錠剤の製造方法 | |
| JP2015522629A (ja) | 薬用粘土製剤 | |
| JP6285952B2 (ja) | 高含量のイブプロフェンナトリウム顆粒、これらの調製、及び非発泡性固体剤形の調製におけるこれらの使用 |